Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;198(1):1-9.
doi: 10.1007/s10549-022-06850-7. Epub 2022 Dec 24.

Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines

Chirag Shah  1 , Pat Whitworth  2 , Stephanie Valente  3 , Graham S Schwarz  4 , Megan Kruse  5 , Manpreet Kohli  6 , Kirstyn Brownson  7 , Laura Lawson  2 , Beth Dupree  8 , Frank A Vicini  9
Affiliations
Review

Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines

Chirag Shah et al. Breast Cancer Res Treat. 2023 Feb.

Abstract

Purpose: Breast cancer-related lymphedema (BCRL) represents a significant concern for patients following breast cancer treatment, and assessment for BCRL represents a key component of survivorship efforts. Growing data has demonstrated the benefits of early detection and treatment of BCRL. Traditional diagnostic modalities are less able to detect reversible subclinical BCRL while newer techniques such as bioimpedance spectroscopy (BIS) have shown the ability to detect subclinical BCRL, allowing for early intervention and low rates of chronic BCRL with level I evidence. We present updated clinical practice guidelines for BIS utilization to assess for BCRL.

Methods and results: Review of the literature identified a randomized controlled trial and other published data which form the basis for the recommendations made. The final results of the PREVENT trial, with 3-year follow-up, demonstrated an absolute reduction of 11.3% and relative reduction of 59% in chronic BCRL (through utilization of compression garment therapy) with BIS as compared to tape measurement. This is in keeping with real-world data demonstrating the effectiveness of BIS in a prospective surveillance model. For optimal outcomes patients should receive an initial pre-treatment measurement and subsequently be followed at a minimum quarterly for first 3 years then biannually for years 4-5, then annually as appropriate, consistent with previous guidelines; the target for intervention has been changed from a change in L-Dex of 10 to 6.5. The lack of pre-operative measure does not preclude inclusion in the prospective surveillance model of care.

Conclusion: The updated clinical practice guidelines present a standardized approach for a prospective model of care using BIS for BCRL assessment and supported by evidence from a randomized controlled trial as well as real-world data.

Keywords: Bioimpedance spectroscopy; Breast cancer; Clinical guidelines; L-Dex; Lymphedema.

PubMed Disclaimer

Conflict of interest statement

Chirag Shah- Scientific Consultant ImpediMed, Consultant PreludeX, Consultant Evicore, Consultant Videra Surgical. Frank Vicini- CMO ImpediMed. Stephanie Valente- Oncology Advisory Board/Consultant for ImpediMed, AxoGen, Merit and Pacira. Pat Whitworth- Partner TME LLC, Consultant Impedimed. Graham Schwarz- Consultant Impedimed, Quest Medical Imaging. Megan Kruse declares that she has no conflicts of interest. Manpreet Kohli- Oncology Advisory Board, Impedimed. Kirstyn Brownson- Oncology Advisory Board, Impedimed. Laura Lawson- Oncology Advisory Board, Impedimed. Beth Dupree declares that she has no conflicts of interest.

Figures

Fig. 1
Fig. 1
Reading from SOZO device
See this image and copyright information in PMC

References

    1. Shah C, Vicini FA. Breast cancer-related arm lymphedema: incidence rates, diagnostic techniques, optimal management and risk reduction strategies. Int J Radiat Oncol Biol Phys. 2011;81(4):907–914. doi: 10.1016/j.ijrobp.2011.05.043. - DOI - PubMed
    1. Shih YC, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009 doi: 10.1200/JCO.2008.18.3517. - DOI - PubMed
    1. Lee MJ, Beith J, Ward L, Kilbreath S. Lymphedema following taxane-based chemotherapy in women with early breast cancer. Lymphat Res Biol. 2014;12(4):282–288. doi: 10.1089/lrb.2014.0030. - DOI - PubMed
    1. Jung S-Y, Shin KH, Kim M, et al. Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients. Breast Cancer Res Treat. 2014;148(1):91–98. doi: 10.1007/s10549-014-3137-x. - DOI - PubMed
    1. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016;66(1):43–73. doi: 10.3322/caac.21319. - DOI - PubMed

MeSH terms